- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05373095
Rudi Kundini, Pamoja Kundini (RKPK: Phase II)
Strengthening the Continuity of HIV Care in Tanzania With Economic Support: Phase II
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This protocol describes a 2-armed parallel individually randomized controlled trial for which 692 PLHIV who meet eligibility criteria, are currently accessing care at a participating health facility (Katoro Health Center, Geita Town Council Hospital, Geita Regional Referral Hospital, or Nyankumbu Health Center), and have provided informed consent to be part of the study will be randomized in a 1:1 ratio (n=346 PLHIV in each arm), stratified by site, to the control or intervention group. The investigators will use machine learning to finalize a predictive model based on routinely collected medical and pharmacy record data to identify and recruit PLHIV for participation at participating facilities who are at high-risk for disengaging from HIV care.
Eligible and consenting participants randomized to the control arm will receive standard of care HIV clinical services according to Tanzania's National Guidelines for the Management of HIV. Criteria for enrollment into enhanced adherence counseling sessions includes when client's viral load reaches a detectable level (>1000 copies/ml). Enhanced adherence counseling includes the standard provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions, starting on the day of the result and for two months after. Counseling focuses on the meaning of viral loads and supportive, non-judgmental strategies for adherence and visit attendance. Sessions are conducted in an individual, 1:1 setting with a trained counselor who is on the clinical staff, or in a group setting with a trained counselor who is on the clinical staff. A minimum of three sessions are required. Eligible and consenting participants randomized to the intervention arm will receive the same standard HIV care services plus the offer of a cash transfer paired with visit attendance and attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first payment will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining enhanced adherence counseling sessions. Due to the nature of the intervention, participants will not be blinded to intervention assignment. The primary endpoint is viral load suppression (<1000 copies/ml) at 12 months following study enrollment.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sandra I McCoy, PhD, MPH
- Phone Number: +15106420513
- Email: smccoy@berkeley.edu
Study Locations
-
-
-
Geita, Tanzania
- Not yet recruiting
- Geita Regional Referral Hospital
-
Contact:
- Matilda Mlowe
-
Geita, Tanzania
- Recruiting
- Geita Town Council Hospital
-
Contact:
- Matilda Mlowe
-
Geita, Tanzania
- Not yet recruiting
- Nyankumbu Health Center
-
Contact:
- Matilda Mlowe
-
Katoro, Tanzania
- Recruiting
- Katoro Health Center
-
Contact:
- Matilda Mlowe
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- PLHIV on ART;
- Age 18 years or older;
- Phone ownership OR consistent phone access;
- Not already enrolled in/currently attending enhanced adherence counseling sessions at the facility
- Living in Geita Region and intends to receive care at a study facility for the next 12 months;
- Classified as "high-risk" for loss to follow-up (LTFU) from HIV care, and
- Provides written informed consent for participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Enhanced Adherence Counseling only for those who qualify
Eligible and consenting participants randomized to the control arm will receive standard of care HIV clinical services according to Tanzania's National Guidelines for the Management of HIV.
For those who meet clinic eligibility criteria for enhanced adherence counseling, this includes the standard provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions, starting on the day of a detectable viral load result and for two months after.
Counseling focuses on the meaning of viral loads and supportive, non-judgmental strategies for adherence and visit attendance.
A minimum of three sessions are required.
|
|
Experimental: Adapted Adherence Counseling (PKC) and Conditional Cash Transfers
Eligible and consenting participants randomized to the intervention arm will receive the same standard HIV clinical services according Tanzania's National Guidelines for the Management of HIV as the comparison arm, which includes provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions adapted for study purposes (PKC sessions).
Counseling focuses on the meaning of viral loads and supportive, non-judgmental strategies for adherence and visit attendance.
A minimum of three sessions are required.
In addition to enhanced adherence counseling, intervention participants will receive the offer of a cash transfer paired with attendance at each of the three enhanced adherence counseling sessions.
The first payment will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining enhanced adherence counseling sessions.
|
The intervention includes up to 3 cash transfers of 22,500 Tanzanian Shillings (~$10) paired with attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions).
The first cash transfer will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining PKC sessions.
The cash transfers will include extra funds for transaction fees, typically <$1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
12-Month Viral Suppression
Time Frame: 12 months
|
The proportion of people living with HIV (PLHIV) and on ART with suppressed HIV viral load ( <1000 copies/ml) at 12 months after study enrollment.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6-month retention in care
Time Frame: 6 months
|
The proportion of people living with HIV (PLHIV) on ART at 6 months after study enrollment (PEPFAR considers those not retained on ART to include those who died, disengaged from care, stopped ART, or had no evidence of care for ≥28 days after a missed visit.
Participants not found after exhaustive tracing efforts to rule out silent transfers will be classified as not retained on ART)
|
6 months
|
12-month retention in care
Time Frame: 12 months
|
The proportion of people living with HIV (PLHIV) on ART at 12 months after study enrollment (PEPFAR considers those not retained on ART to include those who died, disengaged from care, stopped ART, or had no evidence of care for ≥28 days after a missed visit.
Participants not found after exhaustive tracing efforts to rule out silent transfers will be classified as not retained on ART)
|
12 months
|
12-month Appointment Attendance
Time Frame: 12 months
|
The proportion of scheduled visits that were completed during the 0-12 month period
|
12 months
|
6-month Appointment Attendance
Time Frame: 6 months
|
The proportion of scheduled visits that were completed during the 0-6 month period
|
6 months
|
12-month Mortality
Time Frame: 12 months
|
The cumulative incidence of mortality at 12 months after study enrollment
|
12 months
|
6-month Predictive value positive (PVP) of machine learning algorithm
Time Frame: 6 months
|
Predictive value positive (PVP) of the machine learning algorithm in identifying PLHIV at-risk of disengagement from HIV care within 6 months
|
6 months
|
12-month Predictive value positive (PVP) of machine learning algorithm
Time Frame: 12 months
|
Predictive value positive (PVP) of the machine learning algorithm in identifying PLHIV at-risk of disengagement from HIV care within 12 months
|
12 months
|
6-month PVP of routine clinical criteria
Time Frame: 6 months
|
PVP of the routine clinical criteria (i.e.
recent missed visit or detectable viral load, >1000 copies/ml) for identifying PLHIV at-risk of disengagement from HIV care within 6 months
|
6 months
|
12-month PVP of routine clinical criteria
Time Frame: 12 months
|
PVP of the routine clinical criteria (i.e.
recent missed visit or detectable viral load, >1000 copies/ml) for identifying PLHIV at-risk of disengagement from HIV care within 12 months
|
12 months
|
6-month Predictive value negative (PVN) of the machine learning algorithm
Time Frame: 6 months
|
Predictive value negative (PVN) of the machine learning algorithm in identifying PLHIV not at-risk of disengagement from HIV care within 6 months
|
6 months
|
12-month PVN of the machine learning algorithm
Time Frame: 12 months
|
PVN of the machine learning algorithm in identifying PLHIV not at-risk of disengagement from HIV care within 12 months
|
12 months
|
6-month PVN of routine clinical criteria
Time Frame: 6 months
|
PVN of the routine clinical criteria for identifying PLHIV not at-risk of disengagement from HIV care within 6 months
|
6 months
|
12-month PVN of routine clinical criteria
Time Frame: 12 months
|
PVN of the routine clinical criteria for identifying PLHIV not at-risk of disengagement from HIV care within 12 months
|
12 months
|
Enhanced Adherence Counseling Session Attendance
Time Frame: 6 months
|
Proportion of enhanced adherence counseling sessions completed among sessions scheduled
|
6 months
|
Viral Suppression with enhanced adherence counseling completion
Time Frame: 6 months
|
Proportion with HIV viral suppression after completion of enhanced adherence counseling sessions
|
6 months
|
12-month durable viral load
Time Frame: 12 months
|
Proportion with durable HIV viral suppression 12 months after enrollment: at least 2 viral load measurements taken from up to 6 months prior to study enrollment and up to and including 12 months following study enrollment and all are undetectable (<1000 copies/ml) will have met criteria for durable viral suppression at 12 months.
|
12 months
|
6-Month Viral Suppression (<1000 copies/ml)
Time Frame: 6 months
|
The proportion of people living with HIV (PLHIV) and on ART with suppressed HIV viral load ( <1000 copies/ml) at 6 months after study enrollment.
|
6 months
|
6-Month Viral Suppression (<50 copies/ml)
Time Frame: 6 months
|
The proportion of people living with HIV (PLHIV) and on ART with suppressed HIV viral load ( <50 copies/ml) at 6 months after study enrollment.
|
6 months
|
12-Month Viral Suppression (<50 copies/ml)
Time Frame: 12 months
|
The proportion of people living with HIV (PLHIV) and on ART with suppressed HIV viral load ( <50 copies/ml) at 12 months after study enrollment.
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sandra I McCoy, PhD, MPH, University of California, Berkeley
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- R01MH125746 - Phase II
- R01MH125746 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV (Human Immunodeficiency Virus)
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
RTI InternationalCenters for Disease Control and PreventionCompletedHuman Immunodeficiency Virus (HIV) PositiveUnited States
-
Bristol-Myers SquibbCompleted
-
Janssen-Cilag International NVCompletedHuman Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) VirusFrance, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
-
Merck Sharp & Dohme LLCRecruitingHuman Immunodeficiency Virus (HIV) InfectionUnited States, Mexico, Russian Federation, South Africa, Thailand
-
Janssen Inc.CompletedHuman Immunodeficiency Virus (HIV)Canada
-
Auritec PharmaceuticalsEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHuman Immunodeficiency Virus (HIV) ProphylaxisUnited States
-
Columbia UniversityNational Institute of Allergy and Infectious Diseases (NIAID); New York University and other collaboratorsCompletedHIV (Human Immunodeficiency Virus)Swaziland
-
Columbia UniversityMinistry of Health, SwazilandCompleted
Clinical Trials on PKC (adapted adherence counseling) and Conditional Cash Transfers
-
Columbia UniversityNational Institute on Drug Abuse (NIDA); University of Miami; Weill Medical College... and other collaboratorsRecruitingHIV Prevention | Opioid Use | HCV | Intravenous Drug UsageCanada, United States
-
Washington University School of MedicineUniversity of Colorado, Denver; University of California, Berkeley; University... and other collaboratorsActive, not recruiting
-
New York UniversityUniversity of Nairobi; Impact Research & Development OrganizationCompletedGender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth) (MP3-Youth)HIV | Adolescent Behavior | GenderUnited States, Kenya